Advancements in Nanotechnology for Targeted Drug Delivery in Chronic Obstructive Pulmonary Disease

Abstract: Nanotechnology has emerged as a transformative platform in the management of chronic obstructive pulmonary disease (COPD), offering targeted, sustained, and patient-friendly therapeutic solutions. Engineered nanocarriers, including liposomes, solid lipid nanoparticles, dendrimers, nanoemulsions, and polymeric nanoparticles enable the precise delivery of bronchodilators, anti-inflammatory agents, gene therapies, and prodrugs directly to inflamed lung tissues. Surface modification with PEG or targeting ligands enhances mucus penetration, circulation time, and receptorspecific uptake while minimizing systemic exposure. Prodrug-loaded nanoparticles remain stable during inhalation and undergo site-specific activation in the diseased pulmonary environment, improving therapeutic efficacy and reducing off-target effects. Furthermore, regenerative medicine approaches, including nanoparticle-assisted stem cell delivery, have shown promise in promoting lung tissue repair and immunomodulation. In addition, an antioxidant nanoparticles, such as gold, cerium oxide, and zinc-based systems, effectively scavenge reactive oxygen species and reduce inflammation, addressing a key pathogenic mechanism in COPD. In vivo studies demonstrate improved lung function, reduced cytokine levels, and enhanced bioavailability using these nano-based strategies. Collectively, these advancements signify a paradigm shift in COPD treatment from broad symptom relief to precision-targeted molecular intervention. With further clinical translation, nanotechnology holds the potential to revolutionize disease management, restoring respiratory function and enhancing quality of life for millions of patients worldwide.